

Stomach function in Parkinson's disease: a feasibility study

Submission date 09/01/2025	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/01/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 11/07/2025	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Parkinson's disease (PD) is the second most common neurodegenerative disease and affects 1% of people over the age of 60 years in industrialised countries. In Aotearoa New Zealand, the number has increased from about 7,000 in 2006 to about 11,000 in 2020.

There is significant diversity in symptoms in people with PD which encompass the conventional movement symptoms including tremor and rigidity. Over the past decade, there has been increasing recognition that non-movement symptoms have a more profound and negative impact on quality of life and wellbeing than movement problems in PD. Many of these affect the digestive system including the stomach, and these symptoms can impair dietary intake and negatively impact nutritional health.

This study aims to explore how feasible it is to conduct a study investigating the use of a device (body surface gastric mapping) to explore gastric (stomach) symptoms in people with PD.

Who can participate?

Patients aged 18 years and over with PD

What does the study involve?

Each participant is invited to one visit only. Participants will be asked to fast overnight for 6-8 hours and to arrive at the University of Auckland in the morning time at a pre-arranged time. They are asked to take all of their usual medications at home before their visit and to bring any medications to take during the visit. They are welcome to bring a member of their family, a caregiver, whānau or friend to the visit and they can stay with the participant during the visit. Height, weight and blood pressure will be measured and participants will be asked some questions and also to complete a number of questionnaires about their PD. Some measurements will be taken to record their movement.

They will be asked to recline on a comfortable chair and a device will be placed on the stomach that measures electrical responses. This is called a body surface gastric mapping device. The sensors are non-invasive, and participants are unlikely to feel much when measurements are being taken. The sensors are positioned and worn like an item of clothing. Participants are given a meal of a muesli bar and a milky drink and measurements will be taken for the next 4 hours. When the study is over, participants and caregivers will be offered lunch before going home.

What are the possible risks and benefits of participating?

The results will help to inform the development of further studies and trials. There are no significant benefits and no significant risks.

Where is the study run from?

The study is being run from the Liggins Institute at the University of Auckland (New Zealand)

When is the study starting and how long is it expected to run for?

May 2023 to August 2025

Who is funding the study?

1. Health Research Council of New Zealand

2. University of Auckland (New Zealand)

Who is the main contact?

Dr Fiona Lithander, fiona.lithander@auckland.ac.nz

Contact information

Type(s)

Principal Investigator

Contact name

Dr Fiona Lithander

Contact details

Liggins Institute

University of Auckland

85 Park Road

Grafton

Auckland

New Zealand

1123

+64 (0)99236691

fiona.lithander@auckland.ac.nz

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

2024 EXP 20400

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

2024 EXP 20400

Study information

Scientific Title

Gastric function in Parkinson's disease: a feasibility study

Acronym

GastricPD

Study objectives

To test the feasibility of the use of a medical technology (body surface gastric mapping and symptom tracking) to measure gastric symptoms and electrophysiology in Parkinson's disease.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 23/05/2023, Southern Health and Disability Ethics Committee (133 Molesworth Street, Wellington, 6011, New Zealand; +64 (0)4 496 2000; hdec@health.govt.nz), ref: 2024 EXP 20400

Study design

Observational feasibility study

Primary study design

Observational

Secondary study design

Feasibility

Study setting(s)

University/medical school/dental school

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Parkinson's disease

Interventions

Each participant is invited to one visit only. Participants will be asked to fast overnight for 6-8 hours and to arrive at the University of Auckland in the morning time at a pre-arranged time. They are asked to take all of their usual medications at home before their visit and to bring any medications to take during the visit. They are welcome to bring a member of their family, a caregiver, whānau or friend to the visit and they can stay with the participant during the visit.

Height, weight and blood pressure will be measured and participants will be asked some questions and also to complete a number of questionnaires about their PD. Some measurements will be taken to record their movement.

They will be asked to recline on a comfortable chair and a device will be placed on the stomach that measures electrical responses. This is called a body surface gastric mapping device. The sensors are non-invasive, and participants are unlikely to feel much when measurements are being taken. The sensors are positioned and worn like an item of clothing. Participants are given a meal of a muesli bar and a milky drink and measurements will be taken for the next 4 hours. When the study is over, participants and caregivers will be offered lunch before going home.

Intervention Type

Other

Primary outcome measure

1. Recruitment rate, number of eligible participants, and length of time taken to recruit 10 participants measured using standard questions by 6 months.
2. Feasibility and acceptability of the measurement of gastric symptoms using the body surface gastric mapping device in 10 participants using existing questions by 6 months

Secondary outcome measures

1. Participant acceptability of completion of questionnaires listed here, assessed using standard questions at baseline
2. Quality of life measured using Parkinson's Disease Questionnaire 8 at baseline
3. Motor and non-motor symptoms measured using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) at baseline
4. Non-motor symptoms measured using the Movement Disorder Society Non-Motor Symptom Rating Scale (MDS NMS) at baseline
5. Gastrointestinal symptoms measured using the Gastrointestinal Symptom Rating Scale at baseline
6. Gastrointestinal symptoms measured using the MDS Gastrointestinal Dysfunction Scale for Parkinson's Disease at baseline
7. Dietary intake measured using intake24 at baseline
8. Gastric electrophysiological and symptom response to a standard test meal in Parkinson's up to 4 hours post consumption of the test meal compared with a matched control group

Overall study start date

23/05/2023

Completion date

30/08/2025

Eligibility

Key inclusion criteria

1. Aged ≥ 18 years
2. A diagnosis of idiopathic PD, diagnosed by a neurologist
3. Available to attend the Liggins Institute at the Grafton campus of the University of Auckland
4. The mental capacity to consent to participate in this research

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

10

Total final enrolment

10

Key exclusion criteria

1. People with medical, cognitive, or psychosocial issues that would preclude compliance with the protocol, confirmed by a principal investigator or neurologist
2. Co-enrolment in another study or trial that, in the opinion of the principal investigators, would interfere with adherence to study requirements

Date of first enrolment

04/02/2025

Date of final enrolment

12/05/2025

Locations

Countries of recruitment

New Zealand

Study participating centre

Liggins Institute, University of Auckland

85 Park Road

Grafton

Auckland

New Zealand

1123

Sponsor information

Organisation

University of Auckland

Sponsor details

Private Bag 92019
Auckland
New Zealand
1142
+64 (0)99236691
dana.wensley@auckland.ac.nz

Sponsor type

University/education

Website

<https://www.auckland.ac.nz/>

ROR

<https://ror.org/03b94tp07>

Funder(s)

Funder type

Research council

Funder Name

Health Research Council of New Zealand

Alternative Name(s)

HRCNewZealand, HRC New Zealand, HRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

New Zealand

Funder Name

University of Auckland

Alternative Name(s)

University of Auckland, New Zealand, UoA

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

New Zealand

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal

Intention to publish date

30/08/2026

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from the principal investigator Dr Fiona Lithander (fiona.lithander@auckland.ac.nz)

IPD sharing plan summary

Available on request